今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

申洲国际获美银看好 目标价上调至93.5港元 尾盘涨超3%

香港，2024年6月14日 - 申洲国际（02313）今日股价强劲上涨，尾盘涨幅收窄至3.07%，报85.55港元，成交额4.05亿港元。美银证券当日发布研报，上调申洲国际今明两年盈利预测，并上调目标价4%至93.5港元，维持“买入”评级。

美银证券表示，上调盈利预测主要基于以下几个原因：

• 订单表现优于预期: 美银预计，申洲国际2024年订单将增长10%，高于市场预期8%。这主要得益于公司在数据中心、新能源汽车和5G等高增长细分市场的领先地位。
• 利润率复苏: 美银预计，申洲国际2024年和2025年的利润率将分别达到10.5%和11.0%，高于市场预期10%和10.5%。这主要得益于公司生产效率的提高和成本控制的改善。

美银证券还表示，虽然投资者对申洲国际的估值有所关注，但他们认为当前的溢价是合理的，并预计公司未来将继续受益于行业增长和自身经营效率的提高。

此外，美银证券还强调，若申洲国际上半年业绩表现强劲，2025年的表现将成为市场主要关注点。

申洲国际是一家领先的集成电路封装测试服务供应商，在全球拥有17家生产基地和5个研发中心。公司主要为智能手机、计算机、数据中心、汽车电子等领域的客户提供服务。

新的标题：

申洲国际获美银看好 订单利润率双双增长 目标价上调至93.5港元

分析人士认为，申洲国际未来仍有望保持强劲增长势头。